Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

36.94USD
19 Jan 2018
Change (% chg)

$-0.05 (-0.14%)
Prev Close
$36.99
Open
$37.19
Day's High
$37.28
Day's Low
$36.50
Volume
29,538,600
Avg. Vol
16,434,462
52-wk High
$37.37
52-wk Low
$30.90

Select another date:

Thu, Jan 18 2018

BRIEF-Kite Announces Clinical Collaboration With Pfizer

* KITE ANNOUNCES CLINICAL COLLABORATION TO EVALUATE INVESTIGATIONAL COMBINATION OF YESCARTA™ (AXICABTAGENE CILOLEUCEL) AND PFIZER’S UTOMILUMAB IN LARGE B-CELL LYMPHOMA

BRIEF-Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio

* FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO

BRIEF-Novartis poaches Pfizer oncology head Elizabeth Barrett

* Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the Executive Committee of Novartis, effective February 1, 2018

BRIEF-Basilea Announces Completion Of License Agreement Extension With Pfizer

* BASILEA ANNOUNCES COMPLETION OF THE LICENSE AGREEMENT EXTENSION WITH PFIZER FOR ANTIFUNGAL CRESEMBA FOR CHINA AND ASIA PACIFIC Source text for Eikon: Further company coverage: (Gdynia Newsroom)

GSK CEO says looking at Pfizer consumer business, but not a priority

GlaxoSmithKline's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc's consumer products business, but would not overpay for the asset.

GSK CEO says looking at Pfizer consumer business, but not a priority

Jan 9 GlaxoSmithKline's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc's consumer products business, but would not overpay for the asset.

Pfizer ends research for new Alzheimer's, Parkinson's drugs

(In this January 7 story corrects paragraph 3 to show that tanezumab is not yet on the market)

CORRECTED-Pfizer ends research for new Alzheimer's, Parkinson's drugs

NEW YORK, Jan 7 Pfizer Inc is abandoning research to find new drugs aimed at treating Alzheimer's and Parkinson's disease, the U.S. pharmaceutical company announced on Saturday.

BRIEF-Pfizer Announces Expiration, Results Of Tender Offer For Its 5.750 pct

* PFIZER INC. ANNOUNCES EXPIRATION AND RESULTS OF ITS TENDER OFFER FOR ITS 5.750 PER CENT. NOTES DUE 2021 AND RELATED SOLICITATION OF CONSENTS

BRIEF-Pfizer Establishes New Partnering Model For Early-Stage Academic Research

* PFIZER ESTABLISHES NEW PARTNERING MODEL FOR EARLY-STAGE ACADEMIC RESEARCH Source text for Eikon: Further company coverage:

Select another date: